US$ 26.66
glp 1 and gip dual agonist Upcoming wave of hormone-based therapies set to change field of diabetes, obesity care The Emerging Role of Dual
Description
Data gaps in smaller markets are bridged with regional analogs indexed to purchasing power parity

Wright Currently approved GLP-1 receptor agonists for treating type 2 diabetes and, in some cases, obesity, include dulaglutide (Trulicity, Eli Lilly & Co.), exenatide (Byetta, Amylin Pharmaceuticals

Oral formulations are also emerging, which may improve accessibility and further increase uptake

Clinical trials show patients on Semaglutide lose an average of 1517% of body weight, while Tirzepatide patients have seen up to 2225% weight loss
